Discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and promising trial results ...

The recommendation to add COPIKTRA ( duvelisib) to the NCCN Guidelines is based on the broad body of evidence and uniform consensus ( > 85% support of the NCCN Panel) that intervention is appropriate.

In this video, Matthew S. Davids, MD, spoke about the BRUIN-314 trial, one of the first head-to-head studies to compare pirtobrutinib, a noncovalent Bruton tyrosine kinase inhibitor, with ibrutinib, a ...

Following the expanded approval, the accelerated approval for the later-line CLL/SLL was converted to a traditional approval.

Nurix Therapeutics, Inc. ($NRIX) announced an update on their ongoing clinical study. Study Overview: Nurix Therapeutics, Inc. (NRIX) is currently ...

Ascentage Pharma's first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

"What you have said is a terrible, terrible distortion of all the facts." -- CDC Advisory Committee on Immunization Practices ...

As of Wednesday, December 17, Estrella Immunopharma, Inc.’s ESLA share price has surged by 7.90%, which has investors ...

Healio spoke with Matthew S. Davids, MD, about a recent study comparing continuous treatment with a Bruton tyrosine kinase inhibitor with time-limited venetoclax-based therapy for chronic lymphocytic ...

At the 2025 ASH Annual Meeting and Exposition, researchers presented new findings that may meaningfully affect how patients ...

BeOne Medicines’ fair value estimate has nudged higher to about $402 per share, even as the assumed revenue growth rate eases slightly to roughly 17.20%. This reflects a more balanced long term ...